Progress of Regulatory T Lymphocytes and Mesenchymal Stem Cells in Acute Graft Versus Host Disease
GUO Wenwen, PANG Aiming*, JIANG Erlie*
The first-line treatment of aGVHD (acute graft-versus-host disease) is glucocorticoid, but the specificity of drug therapy is poor, which will increase the risk of infection and relapse after allo-HSCT (allogeneic hematopoietic stem cell transplantation). Moreover, the outcome of glucocorticoid-resistant GVHD (graft-versushost disease) is not good, and there is still a lack of standard second-line treatment of aGVHD. Recently, with the understanding of immunomodulatory cells, it has been found that these cells might play a unique role in the prevention and treatment of aGVHD. Therefore, the application of immune cells in the treatment of GVHD has attracted extensive attention. Treg and MSCs are the most widely studied. To better understand the mechanisms of immune regulatory cells regulating GVHD and the feasibility and effectiveness of clinical application, this review mainly reviews the biological characteristics of Treg and MSCs, as well as the research of Treg and MSCs in the therapy of GVHD.
CN
EN